This phase III trial is designed to explore a higher radiation dose by using IMRT simultaneous integrated boost technique with or without concurrent chemotherapy for esophageal carcinoma with limited lymph node metastasis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
164
PTV:50.4Gy/28f, PGTV:59.92Gy/28f
45-50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Beijing, Beijing Municipality, China
RECRUITINGOverall survival(OS)
Time frame: 1 year
Overall survival(OS)
Time frame: 2 year
Overall survival(OS)
Time frame: 3 year
Progress free survival(PFS)
Time frame: 1 year
Progress free survival(PFS)
Time frame: 2 year
Progress free survival(PFS)
Time frame: 3 year
Local recurrence-free rate(LRFS)
Time frame: 1 year
Local recurrence-free rate(LRFS)
Time frame: 2 year
Local recurrence-free rate(LRFS)
Time frame: 3 year
Completion Rate
the completion rate of each arm
Time frame: up to 2 year
Adverse events
Time frame: up to 5 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy